Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Published:2017-11-23 Issue:21 Volume:130 Page:2317-2325
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Mueller Karen Thudium¹,Maude Shannon L.²³,Porter David L.³,Frey Noelle³,Wood Patricia¹,Han Xia¹,Waldron Edward¹,Chakraborty Abhijit¹,Awasthi Rakesh¹,Levine Bruce L.³,Melenhorst J. Joseph³,Grupp Stephan A.²³,June Carl H.³,Lacey Simon F.³

Affiliation:

1. Novartis Pharmaceuticals Corporation, East Hanover, NJ;

2. Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA; and

3. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Abstract

Key Points Tisagenlecleucel (CTL019) has demonstrated clinical efficacy in relapsed/refractory B-cell ALL and CLL. The cellular kinetic profile of tisagenlecleucel was consistent across the 2 diseases, with higher exposure in responding vs nonresponding patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/21/2317/1403776/blood786129.pdf

Reference33 articles.

1. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo;Milone;Mol Ther,2009

2. CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy;Bridgeman;Clin Exp Immunol,2014

3. 4-1BB signaling activates the t cell factor 1 effector/β-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T Cells;Lee;PLoS One,2013

4. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019) [abstract];Grupp;Blood,2015

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines;Blood Advances;2024-02-13

2. “Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy”;npj Systems Biology and Applications;2024-01-26

3. Biomaterials to enhance adoptive cell therapy;Nature Reviews Bioengineering;2024-01-26

4. Predictive model for CAR‐T cell therapy success in patients with relapsed/refractory B‐cell acute lymphoblastic leukaemia;Scandinavian Journal of Immunology;2024-01-16

5. Combined use of NK cells and radiotherapy in the treatment of solid tumors;Frontiers in Immunology;2024-01-09